The effect of fluvastatin on parameters of bone remodeling

Osteoporosis International

Volumn 12, Issue 5, 2001, Pages 380-384

  Bjarnason, N H ^a   Riis, B J ^a   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Bone formation; Bone resorption; Fluvastatin; Lipids; Postmenopausal osteoporosis; Vitamin C

Indexed keywords

ALKALINE PHOSPHATASE; ASCORBIC ACID; CHOLESTEROL; FLUINDOSTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN;

AGED; ARTICLE; BONE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ASCORBIC ACID; BIOLOGICAL MARKERS; BONE REMODELING; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LIPOPROTEINS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0034957690     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980170106     Document Type: Article

References (20)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial
4. Stimulation of bone formation in vitro and in rodents by statins
5. Ascorbic acid and atherosclerotic cardiovascular disease
6. Interlaboratory standardization of measurements of glucohaemoglobins
7. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
8. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies
9. Applications of an enzyme immunoassay for a new markers of bone resorption (CrossLaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment
10. Clinical evaluation of the Serum Cross Laps One Step ELISA, a new assay measuring the serum concentration of bone derived degradation products of type I collagen C-telopeptides
11. Lipid clearing agents in steroid-induced osteoporosis
12. Tibolone: Prevention of bone loss in late postmenopausal women
13. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
14. The effects of raloxifene on bone mineral density, serum cholesterol and uterine endometrium in postmenopausal women
15. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: Effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects
16. Serum bone Gla-protein: A specific marker for bone formation in postmenopausal osteoporosis
17. Alkaline phosphatase and the measurement of bone formation
18. An early response in biochemical markers predicts long-term response in bone mass during HRT in early postmenopausal women
19. Serum CrossLaps for monitoring the response in individuals undergoing anti-resorptive therapy
20. Insulin resistance: Syndrome or tendency?